TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed prostate cancer~  * T1-3, any G (any Gleason), N0 or NX~* High risk defined as G3 or Gleason more than 6 or PSA more than 20 ng/mL and unfit or unwilling to undergo local curative therapy OR~* Low risk defined as G1-2 or Gleason less than 7 and PSA no more than 20 ng/mL and no prior local curative therapy~* Asymptomatic (pain score of 0)~* PSA no more than 100 ng/mL (no more than 25 times normal)~* No metastatic disease by chest x-ray, bone scan (if PSA more than 10 ng/mL or 2.5 times normal), and pelvic CT (if chance of lymph node metastases is at least 5% by Partin tables)~* No bone disease that would interfere with diagnosis of metastatic disease~PATIENT CHARACTERISTICS:~Age:~* 80 and under~Performance status:~* WHO 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* No other malignancy within the past 5 years except adequately treated basal cell skin cancer~* No psychological, personal, sociological, or geographical condition that would preclude study~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: MALE
- Minimum Age: None
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Novel Controlled Hypo-Perfusion Technique in Partial Nephrectomy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be at least 18 years old scheduled for open partial nephrectomy~Exclusion Criteria:~* No prior diagnosis of renal artery disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- hypoperfusion (Type: EXPERIMENTAL): Hypoperfusion of the renal artery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Advanced Non Small Cell Lung Cancer (NSCLC)~* Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 1~* Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy treatment~* Must have at least 1 lesion with measurable disease~Exclusion Criteria:~* Subjects with certain mutations that have not been treated with a targeted therapy prior to enrollment~* Subjects who need daily oxygen therapy~* People with autoimmune disease~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab (Type: ACTIVE_COMPARATOR): Nivolumab Monotherapy - Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator
- Nivolumab & Dasatinib (Type: EXPERIMENTAL): Nivolumab in combination with Dasatinib
- Nivolumab & Relatlimab (Type: EXPERIMENTAL): Nivolumab in combination with Relatlimab
- Nivolumab & Ipilimumab (Type: EXPERIMENTAL): Nivolumab in combination with Ipilimumab
- Nivolumab & BMS-986205 (Type: EXPERIMENTAL): Nivolumab in combination with BMS- 986205

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with advanced or recurrent or metastatic gastrointestinal adenocarcinoma.~* Premature or scheduled termination of standard therapy~* Progressive disease as clinically assessed by the investigator~* Max. tumour lesion ≤ 5 cm~* Adequate organ function~* Ability of patient to understand character and individual consequences of clinical trial~* Age ≥ 18 years~* Written informed consent must be available before any study specific procedure is performed~Exclusion Criteria:~* Patients with severe heart diseases~* Clinical significant ischemic disease during the last 4 weeks before Visit 1~* Severe lung disease~* Symptomatic peritoneal carcinomatosis~* Symptomatic pleural or pericardial effusion~* Serious uncontrolled acute infections less than 3 weeks before Visit 1~* Known dependency on alcohol or other drugs~* Patients requiring corticoids in doses above the Cushing threshold~* Known liver fibrosis or liver cirrhosis~* Any concomitant severe disease which could compromise the objectives of this study in the judgment of the investigator~* Female patient who is pregnant or breast feeding~* Participation in another clinical trial or observation period, respectively, during the last 4 weeks prior to the first IMP dose

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Intraocular Pressures (IOP) During Prolonged Trendelenburg Positioning in Morbidly Obese and Thin Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subjects undergoing prolonged procedures (scheduled \>3hr) in steep Trendelenburg position (eg. robotic prostatectomy, hysterectomy, cystectomy)~2. Morbidly obese subjects: BMI ≥ 35 kg/m2~3. Thin subjects: BMI ≤ 30 kg/m2~4. Age 18-70~5. ASA (American Society of Anesthesiologists) physical status classification I, II, or III~Exclusion Criteria:~1. Known history of glaucoma~2. Note:if initial IOP is noted to be \>21mmHg (millimeters of mercury), patient will be excluded from study and an ophthalmology consultation will be obtained.Surgery will not be postponed.~3. Recent use of IOP lowering topical ophthalmic agents~4. Allergy to latex or proparacaine hydrochloride ophthalmic solution~5. Patients with active corneal epithelial defects or history of recurrent corneal erosion~6. Patients with underlying disorders that can directly increase intraocular pressure (thyroid eye disease, intra orbital tumors, orbital vascular malformation, Sturge-Weber disease, carotid or dural cavernous arteriovenous malformation, cavernous sinus pathology)~7. History of corneal surgery, to include LASIK (laser-assisted in-situ keratomileusis)~8. Any eye surgery within prior 1 month~9. Known pregnancy~10. Cognitive impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- obese patients (Type: None): BMI (body mass index) more than or equal to 35 kg/m2 (weight in kilograms divided by the square of the height in metres)
- Thin patients (Type: None): BMI less than or equal to 30 kg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PHA-739358 for the Treatment of Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* active multiple myeloma progressing after at least 2 prior lines of treatment~* measurable disease~* t(4;14) translocation~* life expectancy of at least 3 months~Exclusion Criteria:~* uncontrolled hypertension~* myocardial infarction, unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the past 6 months.~* pregnancy or breast feeding~* active infections, including HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients with uveitis or retinal vasculitis with unilateral or bilateral macular oedema~* with macular thickness \> 250 micra using OCT~* visual acuity at least 20/200~* with stable treatment with oral prednisone at least during 3 months, either oral ciclosporin or other immunomodulator to treat intraocular inflammatory disease~* patient that can follow study's requirements~* patient who consents to participate~Exclusion Criteria:~* presence of corneal or crystalline opacity preventing observation of fundus of eye~* patients requiring ocular surgery in next 3 months~* one-eyed~* pregnancy and child breastfeeding~* previous history of glaucoma~* on treatment woth an experimental ocular drug~* previous thromboembolism or receiving oral anticoagulant treatment~* vitrectomy~* patients with proved tractional macular pathology associated to macular oedema

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bevacizumab (Type: EXPERIMENTAL): intravitreous bevacizumab 2,5 mg at baseline, week 4 and 8. reinjection is required.
- triamcinolone acetonide (Type: EXPERIMENTAL): intravitreous triamcinolone 2 mg, frequency: 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Different Lipid Emulsions in Acute Lung Injury Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Acute Lung Injury as a result of proven pneumonia (x-ray) or witnessed aspiration~* Oxygenation factor ≤ 300~* \<= 72 hours since intubation or non-invasive ventilatory support by mask at screening~* Expected need for parenteral nutrition for at least 5 days~* Male or female ≥ 18 years of age~Exclusion:~* Exclusion of pregnancy in women with child-bearing potential~* Cardiogenic pulmonary oedema~* Previous (\< 1 month) or ongoing need for corticosteroids \>0.1 mg/kg/d prednisolon-equivalent or other immune suppressive treatment~* Active or previous (\< 1 year) treatment for solid or haematologic malignancy~* Serum triglycerides \> 300 mg/dl at screening~* Alterations of coagulation (thrombocytes \<100 Giga/l), aPTT \> 60 sec, INR ≥ 2.5 without therapeutic intervention~* Autoimmune disease or HIV (according to medical history)~* Known or suspected drug abuse~* General contraindications to infusion therapy :

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): i.v. lipid emulsion for parenteral nutrition
- 2 (Type: ACTIVE_COMPARATOR): i.v. lipid emulsion for parenteral nutrition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of a DNA Immunotherapy to Treat Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Part One and Part Two (8.0 mg dose):~* Histologically confirmed Stage IV or Stage III malignant melanoma, as defined by the American Joint Committee on Cancer (AJCC).~* Must have measurable disease (RECIST 1.0)~Part Two (4.0 mg dose) only:~* Histologically confirmed, resected Stage III or resected Stage IV malignant melanoma, as defined by the AJCC, within 12 months of resection and with no tumour detectable at the time of screening.~Part One and Part Two:~* HLA-A2 positive.~* Positive for HLA-DR4, HLA-DR7, HLA-DR53 or HLA-DQ6.~* Lymphocyte count ≥ 5 x 10e9 cells/mL.~* Serum lactate dehydrogenase (LDH) ≤ upper limit of normal.~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.~* Willing and able to give written, informed consent.~* If male or female of childbearing potential, must be willing to use an effective contraceptive during the course of the study and for three months afterwards.~Exclusion Criteria:~* Known brain metastases at screening.~* Life expectancy of less than three months.~* Patients with TNM classification M1c at screening.~* Prior systemic anti-cancer treatment within four weeks of screening.~* Prior treatment with systemic corticosteroids or other immunosuppressants within four weeks of screening.~* Previous (within five years) or current malignancy at other sites with the exception of curatively treated local tumours such as carcinoma-in-situ of the cervix, basal or squamous cell carcinoma of the skin.~* Pregnant or lactating women.~* Presence of any uncontrolled and significant medical or psychiatric condition which would interfere with trial safety assessments. Caution should be used for patients with suspected or diagnosed epilepsy.~* Any electronic stimulation device such as cardiac demand pacemaker, automatic implantable cardiac defibrillator, nerve stimulators or deep brain stimulators.~* Individuals in which a skin-fold measurement of the cutaneous and subcutaneous tissue for all eligible injection sites (deltoid or quadriceps muscles with intact lymph drainage) exceeds 40 mm.~* Individuals with a heart rate of ≤ 50 beats per minute, history of significant cardiac abnormality and/or significant abnormal baseline electrocardiogram (ECG) readout.~* Treatment with any investigational product within the four weeks preceding screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SCIB1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 12-18 years of age;~* able to swallow whole capsules;~* weighing ≥40kg;~* AST, ALT no more than 3 times the upper limit of normal for age and bilirubin concentrations within normal limits;~* receiving 2 consecutive (within 8 weeks) eligible, though not necessarily identical, IV chemotherapy cycles;~* English speaking (nausea assessment tool (PeNAT30) has been validated only in English)~* cognitive ability of the child believed to be at least at a 4 year old level according to parent or health care professional (to permit self-assessment of nausea severity).~Exclusion Criteria:~* receiving very cisplatin containing chemotherapy (aprepitant capsule administration to these patients is the current standard of care at Sick Kids)~* receiving chemotherapy within 5 days before,during or 5 days after either study cycle that is known or suspected to interact with aprepitant; that is, cyclophosphamide, doxorubicin, daunomycin, etoposide, irinotecan, ifosfamide, imatinib, paclitaxel, topotecan, vinorelbine, vinblastine and vincristine;~* receiving medication known to interact with aprepitant other than dexamethasone (see Appendix I for list of applicable agents and timeframe for exclusion);~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): This group will receive oral aprepitant on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the capsule on the first day of the second study cycle of chemotherapy.
- Group 2 (Type: EXPERIMENTAL): This group will receive an aprepitant capsule on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the oral aprepitant on the first day of the second study cycle of chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has a diagnosis of idiopathic overactive bladder, without incontinence.~* The subject has ≥ 3 urgency episodes over the course of the 3 days immediately preceding the Baseline visit.~* The subject has ≥ 24 episodes of micturition over the course of the 3 days immediately preceding the Baseline visit.~Exclusion Criteria:~* Bladder outlet obstruction (on urodynamic assessment).~* Post-Micturition Residual Volume \> 150 ml (ultrasound assessment).~* Evidence of a urinary tract infection at Screening or Baseline in the study.~* Active or history of interstitial cystitis, malignancy of the bladder or urothelial tract, a carcinoma in situ (non malignant melanoma is allowed) bladder and/or kidney stones.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A - 125 units (Type: EXPERIMENTAL): None
- B - 250 units (Type: EXPERIMENTAL): None
- C - 500 units (Type: EXPERIMENTAL): None
- D (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergone allogeneic cell transplantation ≥21 days prior to dosing~* Meet one of the below criteria:~  1. AdV viremia DNA ≥10,000 copies/mL, OR~ 2. AdV viremia DNA results of ≥1,000 copies/mL, AND~     1. has absolute lymphocyte count \<180/mm3, OR~    2. has received T cell depletion OR~    3. had a cord blood transplant.~Exclusion Criteria:~* Grade 3 or higher acute GVHD~* Ongoing therapy with high-dose systemic corticosteroids~* Uncontrolled viral (other than AdV), bacterial, or fungal infection(s)~* Pregnant or lactating female unwilling to discontinue nursing prior to randomization~* History of severe prior reactions to blood product transfusions~NOTE: Other protocol-defined inclusion/exclusion criterion may apply.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Posoleucel + SoC (Type: EXPERIMENTAL): Posoleucel + SOC; then placebo + SOC for patients who meet optional protocol-defined crossover criteria
- Placebo + SoC (Type: PLACEBO_COMPARATOR): Placebo + SOC; then Posoleucel + SOC for patients who meet optional protocol-defined crossover criteria

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Topical Use of Difinsa53™ to Prevent Radiation Dermatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients 18 years and older~* Pathologic diagnosis of breast cancer requiring radiation therapy to whole breast~* Able to apply lotion to treatment area at least twice daily during radiation course~* All surgical sites healed~* No evidence of infection~* No history of sensitivity to any component in Aquaphor or Difensa53~Exclusion Criteria:~* Prior history of radiation therapy (RT) to that site~* Known dermatologic conditions affecting skin in radiation port~* Concurrent chemotherapy~* Skin infection in radiation port~* History of sensitivity to Aquaphor or Difensa53 component

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy